Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]
Abstract
[This corrects the article DOI:...
Paper Details
Title
Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]
Published Date
Aug 1, 2020
Journal
Volume
33
Pages
100590 - 100590
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History